IRWD on Nasdaq
Ironwood Pharmaceuticals
American pharmaceutical company
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery.3 Its shares trade on Nasdaq under the symbol IRWD.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
1998Founded1
Compare with Evolus, Inc., RIGEL PHARMACEUTICALS INC or Xeris Biopharma Holdings, Inc., or pick any stock.
- TickerIRWD on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersCambridge1
- Websitewww.ironwoodpharma.com
- Legal formDelaware corporation1
- Incorporated inDE5
- Business address100 Summer Street, Suite 2300, Boston, Ma 021105
- Filer categoryAccelerated filer, Smaller reporting company5
- LEI549300PC8MR6QHH6P2964
- StatusActive4
- LEI statusLapsed (not renewed)4
- Registered addressc/o The Corporation Trust Company, 19801 Wilmington, United States4
- Registered withDivision of Corporations, Department of State, 28310754
See how the biggest companies compare on our leaderboards
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Collaborative Arrangements brought in 100% of the revenue Ironwood Pharmaceuticals broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Collaborative Arrangements | $351.4M | $296.2M |
| Collaborative arrangement, other agreements | $734.0K | $87.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development32¢$95.1M
- Selling, general and admin28¢$82.3M
- Other costs16¢$48.7M
- Income tax16¢$46.0M
- Profit8¢$24.0M
Out of $296.2M in revenue.7
Where each dollar of operating cash went, fiscal 2025
- Capital spending0¢$34.0K
- Kept or used elsewhere100¢$127.0M
Out of $127.0M of cash from operations.7
Financial statements
Every line of the income statement as filed: the last 2 fiscal years (annual) or 8 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenues | $296.2M | $351.4M |
| Research and development | $95.1M | $111.4M |
| Selling, general and administrative | $82.3M | $144.3M |
| Restructuring, net | $20.3M | $2.6M |
| Total costs and expenses | $197.6M | $258.3M |
| Income from operations | $98.5M | $93.1M |
| Interest expense and other financing costs | -$32.7M | -$33.0M |
| Interest and investment income | $4.1M | $4.5M |
| Other | $193.0K | $640.0K |
| Other income (expense), net | -$28.5M | -$27.9M |
| Income before income taxes | $70.0M | $65.2M |
| Income tax expense | -$46.0M | -$64.3M |
| Net income | $24.0M | $880.0K |
| Net income per share - basic (in dollars per share) | $0.15 | $0.01 |
| Net income per share - diluted (in dollars per share) | $0.15 | $0.01 |
| Weighted average shares used in computing net income per share - basic (in shares) | 161.8M shares | 159.1M shares |
| Weighted average shares used in computing net income per share - diluted (in shares) | 163.0M shares | 160.1M shares |
| Period ending | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | $47.7M | $122.1M | $85.2M | $41.1M | $90.5M | $91.6M | $94.4M | $74.9M |
| Total costs and expenses | $40.9M | $46.6M | $39.9M | $70.3M | $59.1M | $66.0M | $69.4M | $63.9M |
| Other income (expense), net | -$6.3M | -$7.5M | -$7.5M | -$7.2M | -$7.5M | -$8.3M | -$6.1M | -$6.1M |
| Net income | -$2.3M | $40.1M | $23.6M | -$37.4M | $2.3M | $3.6M | -$860.0K | -$4.2M |
| Net income per share - basic (in dollars per share) | -$0.01 | $0.25 | $0.15 | -$0.23 | $0.01 | $0.02 | -$0.01 | -$0.03 |
| Net income per share - diluted (in dollars per share) | -$0.01 | $0.23 | $0.14 | -$0.23 | $0.01 | $0.02 | -$0.01 | -$0.03 |
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $215.5M | $88.6M |
| Accounts receivable, net | $46.7M | $81.9M |
| Prepaid expenses and other current assets | $12.0M | $11.9M |
| Total current assets | $274.2M | $182.4M |
| Property and equipment, net | $3.4M | $4.5M |
| Operating lease right-of-use assets | $9.3M | $11.0M |
| Intangible assets, net | $2.0M | $2.9M |
| Deferred tax assets | $103.4M | $144.2M |
| Other assets | $4.5M | $5.9M |
| Total assets | $396.9M | $350.9M |
| Accounts payable | $2.9M | $2.1M |
| Accrued research and development costs | $3.1M | $6.7M |
| Accrued expenses and other current liabilities | $33.2M | $26.8M |
| Current portion of operating lease liabilities | $3.3M | $3.2M |
| Current portion of convertible senior notes | $199.7M | |
| Total current liabilities | $242.2M | $38.8M |
| Convertible senior notes, net of current portion | $199.0M | |
| Operating lease obligations, net of current portion | $9.9M | $12.3M |
| Revolving credit facility | $385.0M | $385.0M |
| Other liabilities | $21.6M | $17.1M |
| Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 163,058,316 shares issued and outstanding as of December 31, 2025 and 500,000,000 shares authorized and 160,205,899 shares issued and outstanding as of December 31, 2024 | $163.0K | $160.0K |
| Additional paid-in capital | $1.4B | $1.4B |
| Accumulated deficit | -$1.7B | -$1.7B |
| Accumulated other comprehensive income (loss) | -$1.1M | $923.0K |
| Total stockholders' deficit | -$261.8M | -$301.3M |
| Total liabilities and stockholders' deficit | $396.9M | $350.9M |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
| Preferred stock, shares authorized (in shares) | 75.0M shares | 75.0M shares |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares |
| Common stock, shares issued (in shares) | 163.1M shares | 160.2M shares |
| Common stock, shares outstanding (in shares) | 163.1M shares | 160.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $215.5M | $88.6M |
| Accounts receivable, net | $46.7M | $81.9M |
| Prepaid expenses and other current assets | $12.0M | $11.9M |
| Total current assets | $274.2M | $182.4M |
| Property and equipment, net | $3.4M | $4.5M |
| Operating lease right-of-use assets | $9.3M | $11.0M |
| Intangible assets, net | $2.0M | $2.9M |
| Deferred tax assets | $103.4M | $144.2M |
| Other assets | $4.5M | $5.9M |
| Total assets | $396.9M | $350.9M |
| Accounts payable | $2.9M | $2.1M |
| Accrued research and development costs | $3.1M | $6.7M |
| Accrued expenses and other current liabilities | $33.2M | $26.8M |
| Current portion of operating lease liabilities | $3.3M | $3.2M |
| Current portion of convertible senior notes | $199.7M | |
| Total current liabilities | $242.2M | $38.8M |
| Convertible senior notes, net of current portion | $199.0M | |
| Operating lease obligations, net of current portion | $9.9M | $12.3M |
| Revolving credit facility | $385.0M | $385.0M |
| Other liabilities | $21.6M | $17.1M |
| Class A Common Stock, $0.001 par value, 500,000,000 shares authorized and 163,058,316 shares issued and outstanding as of December 31, 2025 and 500,000,000 shares authorized and 160,205,899 shares issued and outstanding as of December 31, 2024 | $163.0K | $160.0K |
| Additional paid-in capital | $1.4B | $1.4B |
| Accumulated deficit | -$1.7B | -$1.7B |
| Accumulated other comprehensive income (loss) | -$1.1M | $923.0K |
| Total stockholders' deficit | -$261.8M | -$301.3M |
| Total liabilities and stockholders' deficit | $396.9M | $350.9M |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
| Preferred stock, shares authorized (in shares) | 75.0M shares | 75.0M shares |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares |
| Common stock, shares issued (in shares) | 163.1M shares | 160.2M shares |
| Common stock, shares outstanding (in shares) | 163.1M shares | 160.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income | $24.0M | $880.0K |
| Depreciation and amortization | $1.9M | $2.0M |
| Loss on disposal of property and equipment | $89.0K | $75.0K |
| Share-based compensation expense | $17.2M | $29.9M |
| Non-cash interest expense | $1.7M | $1.9M |
| Non-cash lease expense | $1.7M | $1.6M |
| Deferred income taxes | $40.8M | $68.1M |
| Accounts receivable, net | $35.1M | $47.2M |
| Prepaid expenses and other current assets | $367.0K | $89.0K |
| Other assets | $447.0K | -$854.0K |
| Accounts payable and accrued expenses | $6.2M | -$20.2M |
| Accrued research and development costs | -$4.1M | -$14.7M |
| Operating lease liabilities | -$2.4M | -$2.2M |
| Other liabilities | $4.0M | -$10.3M |
| Net cash provided by operating activities | $127.0M | $103.5M |
| Purchases of property and equipment | -$34.0K | -$142.0K |
| Net cash used in investing activities | -$34.0K | -$142.0K |
| Proceeds from exercise of stock options and employee stock purchase plan | $216.0K | $11.0M |
| Taxes paid related to net share settlement of share-based awards | -$737.0K | |
| Repayment of 2024 Convertible Notes | -$200.0M | |
| Proceeds from revolving credit facility | $150.0M | |
| Costs associated with revolving credit facility | -$2.2M | |
| Repayments of revolving credit facility | -$65.0M | |
| Net cash provided by (used in) financing activities | $216.0K | -$107.0M |
| Effect of exchange rate changes on cash and cash equivalents | -$329.0K | -$32.0K |
| Net increase (decrease) in cash and cash equivalents | $126.9M | -$3.6M |
| Cash paid for interest | $30.3M | $32.6M |
| Cash paid for income taxes | $3.5M | $8.4M |
No quarter-by-quarter statement was filed.
Corporate structure
Ironwood Pharmaceuticals sits at the top of its group. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Ironwood Pharmaceuticals
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest Aug 14, 2026 (7 filings since Nov 14, 2024)
- State Street Corporation Filed SCHEDULE 13G on Ironwood Pharmaceuticals, latest Aug 7, 2026 (6 filings since Feb 2, 2023)
- BlackRock Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest Jul 28, 2026 (9 filings since Feb 3, 2022)
- RENAISSANCE TECHNOLOGIES LLC Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest May 14, 2026 (2 filings since Nov 13, 2024)
- Bank of America Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest Apr 27, 2026 (2 filings since Nov 14, 2025)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest Mar 27, 2026 (9 filings since Feb 10, 2022)
- Sarissa Capital Management LP Filed SCHEDULE 13D/A on Ironwood Pharmaceuticals, latest Mar 19, 2026
- Barclays Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest Nov 12, 2025 (2 filings since Aug 12, 2025)
- Pacer Advisors, Inc. Filed SCHEDULE 13G/A on Ironwood Pharmaceuticals, latest May 2, 2025 (2 filings since May 2, 2025)
- LSV ASSET MANAGEMENT Filed SC 13G/A on Ironwood Pharmaceuticals, latest Feb 9, 2024 (2 filings since Feb 10, 2023)
- WESTFIELD CAPITAL MANAGEMENT CO LP Filed SC 13G/A on Ironwood Pharmaceuticals, latest Jul 5, 2023 (2 filings since Feb 1, 2022)
- Wellington Management Company Filed SC 13G/A on Ironwood Pharmaceuticals, latest May 10, 2023 (3 filings since Feb 4, 2022)
- Ironwood Pharmaceuticals Boston, Massachusetts, United States
- VectivBio Holding AG Stake · V8
- GlyPharma Therapeutic Inc Subsidiary · Canada
- Ironwood Pharmaceuticals Securities Corporation Subsidiary · Massachusetts, United States
- VectivBio AG Subsidiary · Switzerland
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
What it owns
What Ironwood Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $11.4M7 Dec 31, 2025 | $12.9M7 Dec 31, 2024 | −11.3% |
| Accumulated depreciation | $8.0M7 Dec 31, 2025 | $8.4M7 Dec 31, 2024 | −4.3% |
| Property and equipment, net | $3.4M7 Dec 31, 2025 | $4.5M7 Dec 31, 2024 | −24.2% |
| Operating-lease assets (leased space) | $9.3M7 Dec 31, 2025 | $11.0M7 Dec 31, 2024 | −15.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $215.5M7 Dec 31, 2025 | $88.6M7 Dec 31, 2024 | +143.3% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, net | $2.0M7 Dec 31, 2025 | $2.9M7 Dec 31, 2024 | −28.7% |
Properties, in its own words
Our corporate headquarters are located in Boston, Massachusetts, where, as of December 31, 2025, we occupied approximately 39,000 square feet of office space under our lease expiring in June 2030. We also have operations in Basel, Switzerland. We believe that our facilities are suitable and adequate for our needs for the foreseeable future.
Item 2 of the 10-K filed Feb 26, 2026.15
Leadership
Who has led Ironwood Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
200020052010201520202025
- Chief executive officerThomas A. McCourt Mar 30, 2021 to now16
- Chief executive officerMark Mallon Apr 3, 2019 to Mar 2, 202117
- Chief executive officerPeter M. Hecht Feb 2, 2010 to Apr 3, 201918
- PresidentThomas A. McCourt Apr 3, 2019 to May 26, 202119
- Chief financial officerGregory S. Martini Jan 29, 2025 to now20
- Chief financial officerSravan Kumar Emany Dec 8, 2021 to Nov 20, 202421
- Chief financial officerGina Consylman Nov 14, 2017 to Mar 30, 202122
- Chief financial officerThomas Graney Sep 4, 2014 to Mar 1, 201723
- Chief operating officerSravan Kumar Emany Nov 20, 2024 to Nov 20, 202424
- Chief operating officerJason Rickard Apr 21, 2020 to Mar 10, 202325
- Chief operating officerWilliam Huyett Dec 19, 2017 to Apr 3, 201926
Board members and other officers (35)
- SVP, CMO, Head-Res&DrugJeffrey Silber Jul 22, 2026 to now27
- Chief Commercial OfficerTammi L. Gaskins Mar 21, 2025 to now28
- Principal Accounting OfficerRonald Silver Jul 22, 2021 to now29
- SVP, GC & SecretaryConor Kilroy Apr 21, 2020 to Mar 2, 202130
- CMO, SVP & Head of Drug Devt.Michael Shetzline Apr 21, 2020 to now31
- Executive Senior AdvisorMark Mallon Jan 11, 2019 to Jan 11, 201932
- Chief Admin Officer & SVPHalley E. Gilbert Apr 3, 2019 to Feb 25, 202033
- Chief Accounting OfficerKelly Macdonald Jul 11, 2019 to Dec 8, 202034
- Chief Accounting OfficerGina Consylman Jun 26, 2014 to Aug 22, 201735
- Chief Scientific OfficerMark G. Currie Feb 2, 2010 to Mar 8, 201936
- Chief Commercial OfficerThomas A. McCourt Feb 2, 2010 to Feb 22, 201937
- Board memberThomas A. McCourt Jun 9, 2021 to now38
- Board memberAlexander J. Denner Nov 9, 2020 to now39
- Board memberJay Shepard Dec 3, 2020 to now40
- Board memberCatherine Moukheibir Apr 3, 2019 to now41
- Board memberJon R. Duane Apr 3, 2019 to now42
- Board memberMark G. Currie Apr 3, 2019 to now43
- Board memberMark Mallon Apr 3, 2019 to Mar 2, 202117
- Board memberMarla L. Kessler Apr 3, 2019 to now44
- Board memberAmy W. Schulman Jan 4, 2017 to Apr 3, 201945
- Board memberAndrew Dreyfus Apr 7, 2016 to now46
- Board memberLawrence S. Olanoff Apr 16, 2015 to Jun 4, 202147
- Board memberJulie McHugh Feb 12, 2014 to now48
- Board memberDouglas E. Williams Jun 4, 2014 to Apr 3, 201949
- Board memberEdward P. Owens Mar 5, 2013 to Jun 4, 202150
- Board memberBryan E. Roberts Feb 2, 2010 to Jun 16, 201551
- Board memberChristopher T. Walsh Phd. Feb 2, 2010 to Mar 16, 201752
- Board memberGeorge Conrades Feb 2, 2010 to Jun 5, 201553
- Board memberGina Bornino Miller Feb 2, 2010 to Feb 2, 201054
- Board memberJoseph C. Cook Jr. Feb 2, 2010 to Mar 13, 201555
- Board memberMarsha Fanucci Feb 2, 2010 to Apr 3, 201956
- Board memberPeter M. Hecht Feb 2, 2010 to Apr 3, 201918
- Board memberTerrance McGuire Feb 2, 2010 to Apr 3, 201957
- General counselMinardo John Aug 4, 2021 to now58
- General counselHalley E. Gilbert Mar 5, 2014 to Feb 22, 201959
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- GlyPharma Therapeutic Inc Canada6
- Ironwood Pharmaceuticals GmbH Switzerland6
- Ironwood Pharmaceuticals Securities Corporation Massachusetts6
- VectivBio AG Switzerland6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Aug 6, 20268-K Results of operations60
- Jun 18, 20268-K Executive or director change; Shareholder vote61
- Jun 15, 20268-K Other events62
- May 21, 20268-K Executive or director change63
- May 13, 20268-K Executive or director change64
- May 7, 20268-K Results of operations65
- Mar 11, 20268-K Other events66
- Feb 25, 20268-K Results of operations67
- Jan 2, 20268-K Results of operations68
- Dec 23, 20258-K Entered a material agreement; Other events69
- Nov 26, 20258-K Other events70
- Nov 10, 20258-K Results of operations71
- Mar 30, 2021New chief executive Thomas A. McCourt becomes CEO16
- Apr 3, 2019New chief executive Mark Mallon becomes CEO17
- Feb 3, 2010Went public Listed on NASDAQ1
- Feb 2, 2010New chief executive Peter M. Hecht becomes CEO18
- 1998Founded Founded1
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.24 a share, on Nov 10, 2025.72
When it reported results
- Aug 6, 2026Reported quarterly or annual results60
- May 7, 2026Reported quarterly or annual results65
- Feb 25, 2026Reported quarterly or annual results67
- Jan 2, 2026Reported quarterly or annual results68
- Nov 10, 2025Reported quarterly or annual results71
- Aug 7, 2025Reported quarterly or annual results73
- May 7, 2025Reported quarterly or annual results74
- Apr 25, 2025Reported quarterly or annual results75
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
398 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 205 insider forms, 49 large holders, 72 other. The latest 20:
- Sep 23, 2026144 EDGAR
- Sep 17, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 22, 20264 EDGAR
- Jul 22, 20263 EDGAR
- Jul 9, 20264 EDGAR
- Jul 7, 2026144 EDGAR
- Jun 18, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 16, 2026144 EDGAR
The 398 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
104 open-market trades by officers, directors and large owners since October 2021: 3 buys and 101 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Silver RonaldPFO & PAO | Sale | 127,890 | $4.52 | $578.1K | Form 4 |
| Jun 16, 2026 | McHugh JulieDirector | Sale | 21,571 | $3.73 | $80.5K | Form 4 |
| Mar 17, 2026 | DENNER ALEXANDER JDirector | Sale | 6,730,800 | $3.05 | $20.5M | Form 4 |
| Feb 24, 2026 | Martini Gregory S.Chief Financial Officer | Sale | 11,457 | $3.66 | $41.9K | Form 4 |
| Feb 24, 2026 | John MinardoChief Legal Officer | Sale | 19,053 | $3.66 | $69.7K | Form 4 |
| Feb 24, 2026 | Shetzline MichaelSVP, CMO, Head-Res&Drug | Sale | 17,012 | $3.66 | $62.3K | Form 4 |
| Feb 24, 2026 | Gaskins Tammi LChief Commercial Officer | Sale | 11,239 | $3.66 | $41.1K | Form 4 |
| Feb 24, 2026 | MCCOURT Thomas AChief Executive Officer | Sale | 103,526 | $3.66 | $378.9K | Form 4 |
| Feb 24, 2026 | Silver RonaldPFO & PAO | Sale | 12,621 | $3.66 | $46.2K | Form 4 |
| Feb 23, 2026 | Martini Gregory S.Chief Financial Officer | Sale | 10,487 | $3.81 | $40.0K | Form 4 |
| Feb 23, 2026 | John MinardoChief Legal Officer | Sale | 17,439 | $3.81 | $66.4K | Form 4 |
| Feb 23, 2026 | Shetzline MichaelSVP, CMO, Head-Res&Drug | Sale | 15,570 | $3.81 | $59.3K | Form 4 |
| Feb 23, 2026 | Gaskins Tammi LChief Commercial Officer | Sale | 10,287 | $3.81 | $39.2K | Form 4 |
| Feb 23, 2026 | MCCOURT Thomas AChief Executive Officer | Sale | 94,757 | $3.81 | $361.0K | Form 4 |
| Feb 23, 2026 | Silver RonaldPFO & PAO | Sale | 11,552 | $3.81 | $44.0K | Form 4 |
| Jan 5, 2026 | Silver RonaldPFO & PAO | Sale | 35,416 | $4.60 | $162.9K | Form 4 |
| Nov 17, 2025 | Gaskins Tammi LChief Commercial Officer | Sale | 6,016 | $3.32 | $20.0K | Form 4 |
| Aug 11, 2025 | Gaskins Tammi LChief Commercial Officer | Sale | 1,316 | $0.84 | $1.1K | Form 4 |
| Aug 11, 2025 | John MinardoChief Legal Officer | Sale | 7,754 | $0.84 | $6.5K | Form 4 |
| Aug 11, 2025 | Silver RonaldPFO & PAO | Sale | 2,846 | $0.84 | $2.4K | Form 4 |
All 104 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 7 filings Nov 14, 2024 to Aug 14, 202676
- State Street CorporationSCHEDULE 13G, 6 filings Feb 2, 2023 to Aug 7, 202677
- BlackRockSCHEDULE 13G/A, 9 filings Feb 3, 2022 to Jul 28, 202678
- RENAISSANCE TECHNOLOGIES LLCSCHEDULE 13G/A, 2 filings Nov 13, 2024 to May 14, 202679
- Bank of AmericaSCHEDULE 13G/A, 2 filings Nov 14, 2025 to Apr 27, 202680
- VANGUARD GROUP INCSCHEDULE 13G/A, 9 filings Feb 10, 2022 to Mar 27, 202681
- Sarissa Capital Management LPSCHEDULE 13D/A, 1 filing Mar 19, 202682
- BarclaysSCHEDULE 13G/A, 2 filings Aug 12, 2025 to Nov 12, 202583
- Pacer Advisors, Inc.SCHEDULE 13G/A, 2 filings May 2, 202584
- LSV ASSET MANAGEMENTSC 13G/A, 2 filings Feb 10, 2023 to Feb 9, 202485
- WESTFIELD CAPITAL MANAGEMENT CO LPSC 13G/A, 2 filings Feb 1, 2022 to Jul 5, 202386
- Wellington Management CompanySC 13G/A, 3 filings Feb 4, 2022 to May 10, 202387
- BROWN CAPITAL MANAGEMENT LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202388
Stakes it holds
Ironwood Pharmaceuticals has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- VectivBio Holding AGSC 13D Jul 7, 202389
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Thomas McCourtChief Executive Officer | 68 | $867.6K | $1.9M90 |
| 2025 | Tammi Gaskins*Senior Vice President, Chief Commercial Officer | 53 | $274.4K | $1.2M90 |
| 2025 | Gregory Martini*Senior Vice President, Chief Financial Officer | 38 | $274.4K | $1.2M90 |
| 2024 | Thomas McCourtChief Executive Officer | 68 | $867.6K | $6.1M90 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 17,788,557 | $74.9M | 0.0% | +4,425,627 |
| Armistice Capital, LLC | 13,932,000 | $58.7M | 1.6% | −1,096,000 |
| Sarissa Capital Management LP | 9,188,635 | $38.7M | 21.7% | No change |
| State Street Corp | 8,809,601 | $37.1M | 0.0% | +1,352,657 |
| Bank Of America Corp /de/ | 8,683,803 | $36.6M | 0.0% | +896 |
| Renaissance Technologies LLC | 7,993,226 | $33.7M | 0.0% | −67,847 |
| Vanguard Capital Management LLC | 6,608,508 | $27.8M | 0.0% | +511,054 |
| Aqr Capital Management LLC | 6,465,921 | $27.2M | 0.0% | −1,069,159 |
| Vanguard Portfolio Management LLC | 5,513,355 | $23.2M | 0.0% | −1,168,682 |
| Geode Capital Management, LLC | 4,831,657 | $20.3M | 0.0% | +288,135 |
| Two Sigma Investments, LP | 4,556,089 | $19.2M | 0.0% | −1,292,187 |
| Marshall Wace, Llp | 4,290,093 | $18.1M | 0.0% | −234,971 |
| Jacobs Levy Equity Management, Inc | 4,065,964 | $17.1M | 0.1% | +433,487 |
| Goldman Sachs Group Inc | 3,313,808 | $14.0M | 0.0% | +623,174 |
| Charles Schwab Investment Management Inc | 3,302,242 | $13.9M | 0.0% | −1,435,615 |
| Federated Hermes, Inc. | 3,231,238 | $13.6M | 0.0% | −117,568 |
| Arrowstreet Capital, Limited Partnership | 3,017,089 | $12.7M | 0.0% | −380,153 |
| Dimensional Fund Advisors LP | 2,522,891 | $10.6M | 0.0% | +440,836 |
| Mackenzie Financial Corp | 2,367,493 | $10.0M | 0.0% | +1,807,459 |
| Morgan Stanley | 1,859,914 | $7.8M | 0.0% | +1,035,095 |
| Connor, Clark & Lunn Investment Management Ltd. | 1,811,714 | $7.6M | 0.0% | −23,710 |
| Northern Trust Corp | 1,373,974 | $5.8M | 0.0% | +108,132 |
| Hillsdale Investment Management Inc. | 1,250,428 | $5.3M | 0.1% | +13,800 |
| Wells Fargo & Company/mn | 1,206,198 | $5.1M | 0.0% | +1,147,348 |
| Deutsche Bank Ag\ | 1,158,138 | $4.9M | 0.0% | +33,149 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Ironwood Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARIRONWOOD PHARMACEUTICALS INC2
- CIK0001446847
- Employer ID (EIN)04-340417615
- Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company15
- Incorporated inDelaware15
- Fiscal year endsDecember 312
- Industry code (SIC)2834 Pharmaceutical Preparations2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address100 Summer Street, Suite 2300, Boston, MA 021102
- Phone617-621-77222
- Shares outstanding165,239,947 as of Jul 31, 202613
- Public float$102.7M as of Jun 30, 202515
- AuditorKPMG LLP, Boston, Massachusetts PCAOB ID 185; it also attests to the company’s internal control over financial reporting15
- On EDGAR sinceSep 26, 20082
- Filings1,429 in all: 4 (756), 8-K (191), SC 13G/A (112), 10-Q (50), 3 (46), 144 (44), SC 13G (29), DEFA14A (24)2
All 47 form types
S-8 (21), 10-K (17), SCHEDULE 13G/A (16), DEF 14A (15), CT ORDER (14), UPLOAD (10), ARS (8), CORRESP (7), SCHEDULE 13G (7), 8-K/A (6), D (5), S-3ASR (5), 424B5 (4), S-1/A (4), SC TO-T/A (4), 5 (3), SC 13D/A (3), SC TO-C (3), 10-K/A (2), 424B2 (2), PRE 14A (2), SC 13D (2), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), D/A (1), DEFC14A (1), EFFECT (1), FWP (1), NT 10-K (1), PREC14A (1), PREN14A (1), PRRN14A (1), REGDEX (1), S-1 (1), SC TO-T (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A Common Stock, $0.001 par value | IRWD | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).15
Risk factors and legal proceedings
The risks Ironwood Pharmaceuticals names in Item 1A of its 10-K filed Feb 26, 2026: 47 risks under these headings, as written.15
- In addition to the other information in this Annual Report on Form 10-K, any of the factors described below could significantly and negatively affect our business, financial condition, results of operations or prospects. The trading price of our Class A Common Stock may decline due to these risks.
- Risks Related to LINZESS, Apraglutide and Other Product Candidates
- We are highly dependent on the commercial success of LINZESS (linaclotide) in the U.S. for the foreseeable future.
- We are subject to uncertainty relating to pricing and reimbursement policies in the U.S., including recent and future healthcare reform measures, which, if not favorable for our products, could hinder or prevent our products’ commercial success.
- Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, our products’ or product candidates’ commercial success.
- We must work effectively and collaboratively with AbbVie to market and sell LINZESS in the U.S., and we must adapt our commercial model and market strategy to the evolving landscape for LINZESS to achieve its maximum commercial potential.
- We cannot give any assurance that apraglutide will receive regulatory approval, which is necessary before it can be commercialized.
- The regulatory approval processes in the U.S., in the E.U. and in other foreign jurisdictions are onerous, lengthy, time consuming, expensive and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for apraglutide or our other product candidates, our business will be harmed.
- Our failure to successfully develop and commercialize additional product candidates or approved products would impair our ability to grow and/or adversely affect our business.
- Delays in the completion of clinical testing of any of our products or product candidates could result in increased costs and could delay or limit our ability to generate revenues.
- The pricing of apraglutide and our other product candidates, if and when approved for marketing, will depend in part on pricing and reimbursement strategies adopted by our competitors.
- We face competition and new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat.
The other 36 risks
- Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their development, create unpredictable clinical trial results, impact their regulatory approval or limit their commercial potential.
- Even though LINZESS is approved by the U.S. FDA for use in adult and certain pediatric patients, post-approval development and regulatory requirements still remain, which may present additional challenges, and we may not be successful in obtaining approval for additional indications for LINZESS that we are seeking or may seek in the future.
- We and our linaclotide partners are subject to uncertainty relating to pricing and reimbursement policies outside the U.S., as well as risks relating to the improper importation of linaclotide and sale of counterfeit versions of linaclotide. If such policies are not favorable, or if linaclotide is improperly imported or is counterfeited, our business and financial results could be adversely affected.
- Even though linaclotide is approved for marketing in the U.S. and in a number of other countries, we or our partners may never receive approval to commercialize linaclotide in additional parts of the world.
- If we are unable to successfully partner with other companies to develop and commercialize products and/or product candidates, our ability to grow would be impaired and our business would be adversely affected.
- Risks Related to the VectivBio Acquisition
- We may not realize the expected benefits and anticipated synergies of the VectivBio Acquisition.
- Risks Related to Our Dependence on Third Parties
- Because we work with partners to develop, manufacture and commercialize linaclotide, we and our partners are dependent upon third parties, and our and our partners’ relationships with those third parties, in our and our partners’ efforts to obtain regulatory approval for, and to commercialize, linaclotide, as well as to comply with regulatory and other obligations with respect to linaclotide.
- We rely entirely on contract manufacturers, our partners and other third parties to manufacture linaclotide, apraglutide, and our other product candidates and to distribute linaclotide. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties, or are otherwise unable to manufacture and distribute sufficient quantities to meet demand, our development and commercialization efforts may be materially harmed.
- If any of our linaclotide partners undergoes a change of control or in management, this may adversely affect our collaborative relationship or the success of the commercialization of linaclotide in the U.S. or in the other countries where it is approved, or the ability to achieve regulatory approval, launch and commercialize linaclotide in other territories.
- We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to continue the development of our product candidates, obtain regulatory approval for or commercialize our product candidates and our business could be harmed.
- Risks Related to Regulatory, Legal and Compliance Matters
- We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities.
- We will incur significant liability if it is determined that we are promoting any “off-label” uses of our products.
- If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
- We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; disruptions of our operating results and business; and other adverse business consequences.
- The VectivBio Acquisition increases our exposure to doing business in foreign jurisdictions.
- Risks Related to Intellectual Property
- Limitations on our ability to obtain patent protection and/or the patent rights relating to our products and our product candidates may limit our ability to prevent third parties from competing against us.
- If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in such litigation could have a material adverse effect on our business.
- If we fail to comply with our obligations or have disagreements over contract interpretation in agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business
- relationship with our licensor, the scope of our intellectual property or technology rights could be narrowed and we could lose license rights that are important to our business.
- We may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may harm our business.
- We have received notices of Paragraph IV certifications related to LINZESS in conjunction with ANDAs filed by generic drug manufacturers, and we may receive additional notices from others in the future. We have, and may continue to, become involved in legal proceedings to protect or enforce intellectual property rights relating to our products and our product candidates, which could be expensive and time consuming, and unfavorable outcomes in such proceedings could have a material adverse effect on our business.
- Risks Related to Our Finances and Capital Requirements
- We incurred significant losses from our inception in 1998 through the year ended December 31, 2018, and we may incur losses in future periods.
- We may need additional funding and may be unable to raise capital when needed, which could cause us to delay, reduce or eliminate our corporate or product development or commercialization efforts.
- Our ability to pay principal of and interest on our outstanding debt will depend in part on the receipt of payments from AbbVie under our collaboration agreement for North America.
- Our indebtedness could adversely affect our financial condition or restrict our future operations.
- The capped call transactions entered into in connection with our Convertible Senior Notes may affect the value of our Class A Common Stock.
- Our quarterly and annual operating results may fluctuate significantly.
- Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code, and it is possible that our net operating loss and tax credit carryforwards may expire before we generate sufficient taxable income to use such carryforwards, or that certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our net operating loss and tax credit carryforwards.
- Our ability to use foreign tax loss carryforwards acquired in the VectivBio Acquisition may be limited.
- If the distribution of the shares of Cyclerion Therapeutics, Inc., or Cyclerion, common stock in connection with the Separation is not generally tax- free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.
- General Risk Factors
- We may not be able to manage our business effectively if we lose any of our current management team or if we are unable to attract, motivate and retain key personnel.
- Security breaches and other disruptions to our information technology structure could compromise our information, disrupt our business and expose us to liability, which would cause our business and reputation to suffer.
- Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could negatively impact the market price of our Class A Common Stock.
- If we identify a material weakness in our internal control over financial reporting, it could have an adverse effect on our business and financial results, and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our Class A Common Stock.
- We expect that the price of our Class A Common Stock will fluctuate substantially.
- Our business could be negatively affected as a result of a proxy contest or certain other stockholder actions.
Legal proceedings
Apraglutide
The opening of Item 3, Legal Proceedings.15
Links
- Websitewww.ironwoodpharma.com1
- X (Twitter)x.com/ironwoodpharma1
- YouTubewww.youtube.com/channel/UCegncMu6yBCfIfQrswkoRUQ1
- WikipediaIronwood Pharmaceuticals
- WikidataQ16997309
- SEC EDGARCIK 1446847
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARMark Mallon, Chief executive officer
- 18
- 19SEC EDGARThomas A. McCourt, President
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30SEC EDGARConor Kilroy, SVP, GC & Secretary
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38SEC EDGARThomas A. McCourt, Board member
- 39SEC EDGARAlexander J. Denner, Board member
- 40SEC EDGARJay Shepard, Board member
- 41SEC EDGARCatherine Moukheibir, Board member
- 42SEC EDGARJon R. Duane, Board member
- 43SEC EDGARMark G. Currie, Board member
- 44SEC EDGARMarla L. Kessler, Board member
- 45SEC EDGARAmy W. Schulman, Board member
- 46SEC EDGARAndrew Dreyfus, Board member
- 47SEC EDGARLawrence S. Olanoff, Board member
- 48SEC EDGARJulie McHugh, Board member
- 49SEC EDGARDouglas E. Williams, Board member
- 50SEC EDGAREdward P. Owens, Board member
- 51SEC EDGARBryan E. Roberts, Board member
- 52
- 53SEC EDGARGeorge Conrades, Board member
- 54SEC EDGARGina Bornino Miller, Board member
- 55SEC EDGARJoseph C. Cook Jr., Board member
- 56SEC EDGARMarsha Fanucci, Board member
- 57SEC EDGARTerrance McGuire, Board member
- 58SEC EDGARMinardo John, General counsel
- 59SEC EDGARHalley E. Gilbert, General counsel
- 60SEC EDGARResults of operations
- 61
- 62SEC EDGAROther events
- 63SEC EDGARExecutive or director change
- 64SEC EDGARExecutive or director change
- 65SEC EDGARResults of operations
- 66SEC EDGAROther events
- 67SEC EDGARResults of operations
- 68SEC EDGARResults of operations
- 69
- 70SEC EDGAROther events
- 71SEC EDGARResults of operations
- 72NasdaqNasdaq calendar
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90